ReviewCancer immunology, immunotherapy : CII2006
Cancer vaccines as a therapeutic modality: The long trek.
Review in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019Article
- Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8βFrontiers in immunology · 2018Article
- Establishing the pig as a large animal model for vaccine development against human cancer.Frontiers in genetics · 2015Article
- Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Current topics in medicinal chemistry · 2013Review
- Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Nature reviews. Urology · 2012Review
- Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country.PloS one · 2012Article
- Article
- The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.Cancer immunology, immunotherapy : CII · 2009Article
- Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.US oncology · 2009Article
- RhoC a new target for therapeutic vaccination against metastatic cancer.Cancer immunology, immunotherapy : CII · 2008Article
- Plant-derived EpCAM antigen induces protective anti-cancer response.Cancer immunology, immunotherapy : CII · 2008Article
- Prostate cancer: genes, environment, immunity and the use of immunotherapy.Prostate cancer and prostatic diseases · 2008Review
- New strategy for the identification of squamous carcinoma antigens that induce therapeutic immune responses in tumor-bearing mice.Cancer gene therapy · 2007Article
- Rebuilding immunity in cancer patients.Blood cells, molecules & diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of cancer vaccines has been one of the several false dawns in which initial promising Phase I and Phase II clinical data have not been followed up with conclusive Phase III trials. In this review, we describe some of the successes and failures, and review the most likely reasons for Phase III failure, such as protocol changes, which are common between Phase II and III, and poorly defined patient groups. Nevertheless, significant survival results have been reported with autologous vaccines for colorectal, renal and, more recently, prostate cancer. In addition, it is becoming evident that immunotherapy is potentially synergistic with other treatment modalities, such as chemotherapy, which can reduce T-regulatory activity that inhibits the immune response to cancer vaccines. This potential for synergy should allow cancer vaccines to become part of the standard treatment regimen for many common tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.